RESOLUTION AGREEMENT Clause Samples

A Resolution Agreement clause outlines the terms and conditions under which parties agree to resolve a dispute or outstanding issue. Typically, this clause specifies the actions each party must take, any payments or remedies involved, and the timeline for fulfilling these obligations. Its core practical function is to formalize the settlement of disagreements, ensuring both parties have a clear, enforceable understanding of how the matter will be concluded and preventing future disputes over the same issue.
RESOLUTION AGREEMENT. East Baton Rouge Parish School Board OCR Complaint No. 06191043
View SourceView Similar (12)
RESOLUTION AGREEMENT. In the event that any of the above two metrics set forth in Section 23.4 are violated, a CFO level conference may be required, at Jabil’s sole and absolute discretion, to discuss and develop an acceptable solution to bringing the Company back in compliance with targeted financial ratio. The Company will have the opportunity to provide information supportive of this compliance issue and shall be allowed [***] days from the last reported period to meet the guidelines set forth previously. In the event that at the end of the next reportable period the Company is still not in compliance, Jabil will require a CFO level discussion with the Company with the intention of reducing the working capital requirements to a more suitable level. The Company will have the ability to propose a suitable solution to both parties, such solutions may include: shortening of terms in order to reduce AR, converting a portion of the inventory to consignment by the Company, or some form of cash deposit or letter of credit to reduce exposure levels. If at any time, the Company does not provide a suitable solution, Jabil may, at its sole discretion, require that some of the previous steps be taken in order to continue with the flow of business activity. Once the Company has returned to compliance for a period of [***], business can return as originally established. [***] Information has been omitted and submitted separately to the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
View SourceView Similar (3)
RESOLUTION AGREEMENT. A copy of the Resolution Agreement, dated as of May 1, 1992, as amended, among ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ and Pechiney, as amended, certified as of the Signing Date by ▇▇▇▇▇ ▇▇▇.
View SourceView Similar (2)
RESOLUTION AGREEMENT. The United States Attorney’s Office for the Western District of Virginia and the Environmental Crimes Section of the United States Department of Justice, Environment and Natural Resources Division (collectively referred to as the “United States”) and Inotiv, Inc. (“INOTIV”), pursuant to authority granted by its Board of Directors, enter into this Resolution Agreement (“Agreement”) to resolve the federal criminal investigation related to the conduct described in the Information (attached as Attachment 3) to the Plea Agreement between the United States and Envigo RMS, LLC and Envigo Global Services, Inc. (collectively “ENVIGO”). For purposes of this Agreement, “INOTIV ENTITIES” includes INOTIV and all entities related to INOTIV, including, but not limited to, ENVIGO and all entities related to ENVIGO, and all successors in interest to any of the above listed entities. This Agreement is binding only on the United States Attorney’s Office for the Western District of Virginia and the Environmental and Natural Resources Division of the United States Department of Justice; it does not bind any other component of the Department of Justice, other federal agencies, or any state, local, or foreign law enforcement or regulatory agency, or any other authority.
View Source
RESOLUTION AGREEMENT. Rutgers, The State University of New Jersey (the University) submits this agreement to resolve Compliance Review No. 02-08-6001, which was commenced in 2008,1 and ensure the University's compliance with Title IX of the Education Amendments of 1972 (Title IX), 20 U.S.C. §1681, and its implementing regulation at 34 C.F.R. Part 106, with respect to the following issues raised in the review: equal opportunities to participate in intercollegiate sports, the provision of reasonable opportunities for each sex to receive athletic scholarships and/or grants-in-aid in proportion to the number of students of each sex participating in intercollegiate athletics, the provision of equipment and supplies, the scheduling of games and practice times, the allocation of travel and per diem allowances, the opportunity to receive tutoring and assignment and compensation of tutors, the opportunity to receive coaching and the assignment and compensation of coaches, the provision of locker rooms, practice and competitive facilities, the provision of medical and training facilities and services, the provision of housing and dining facilities and services, the provision of support services, the recruitment of student athletes and publicity. In assessing compliance with this agreement, the Office for Civil Rights (OCR) will compare the availability, quality and kinds of benefits, opportunities, and treatment afforded to the University's male and female athletes in the identified program components to determine whether they are equivalent. Under this equivalency standard, identical benefits, opportunities, or treatment are not required as long as the effects of any differences are negligible. If a comparison of the benefits, opportunities and treatment afforded to males and females in the identified program components indicates that benefits, opportunities, or treatment are not equivalent, the University could still be in compliance with Title IX if the differences are shown to be the result of nondiscriminatory factors, such as the unique aspects of particular sports or athletic activities. The actions to be taken by the University will include but not be limited to, the specific actions discussed in the paragraphs set forth below. The University was found in compliance with Title IX with respect to the issues raised not set forth below.
View Source
RESOLUTION AGREEMENT. Complete if the parent(s) and district/program reach an agreement.
View Source
RESOLUTION AGREEMENT. A copy of the Resolution Agreement, dated as of May 1, 1992, as amended, among Nelson Peltz, Peter May and Pechiney, as amended, certified ▇▇ ▇▇ ▇▇▇ ▇▇▇ning Date b▇ Nelson Peltz.
View Source
RESOLUTION AGREEMENT. The University enters into this Agreement with OCR and commits to take the actions detailed below pursuant to Title IX of the Education Amendments of 1972 (Title IX), 20 U.S.C. § 1681 et seq., and its implementing regulation, 34 C.F.R. Part 106. This Agreement has been entered into voluntarily by OCR and the University and does not constitute an admission by the University as to any finding reached by OCR. The University affirms its continuing obligation, under Title IX, to take immediate and appropriate action to address sexual harassment and sexual violence, prevent its recurrence, eliminate any hostile environment and remedy its effects on any student, employee, third party or the broader University community, as appropriate, in all of its education programs and activities. Over the course of OCR’s review, the University has taken steps to address sexual discrimination, including sexual harassment and sexual violence. Most significantly, during the 2014-2015 academic year, following a period of public comment and extensive community engagement, the University substantially revised its procedures for investigating and resolving reports of sexual harassment and violence against students, employees and third parties.1 OCR finds that, as written, the University’s current policy and procedures comply with the requirement of Title IX that grievance procedures provide for prompt and equitable resolution of complaints. The University has also, among other efforts, created and filled a dedicated Title IX Coordinator position; expanded investigative capacity in the Office of Equal Opportunity Programs; created and filled a Prevention Coordinator position in the Office of the ▇▇▇▇ of Students to develop, evaluate, implement and assess evidence-based prevention strategies that seek to reduce sexual assault, gender-based violence and high-risk activities in student organizations; reviewed and enhanced training and prevention programs for students and employees, including alcohol education programming and other student outreach efforts; secured funding to hire additional mental health counselors; and developed a Title IX website to provide 1 The University adopted the revised policy and procedures on an interim basis on March 30, 2015, and adopted final versions on July 1, 2015. a central resource for Title IX resources and educational materials. The University also formed the President’s Ad Hoc Group on University Climate and Culture to explore policies, practices, ...
View Source

Related to RESOLUTION AGREEMENT

  • Transition Agreement 12.8.1 In the event of termination of this Agreement, whether in its entirety or with respect to the Terminated Territory, Ablynx and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Ablynx will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Ablynx as reasonably necessary for Ablynx to exercise its licenses pursuant to Sections 12.6 and 12.7 with respect to the Licensed Products after termination of this Agreement (in its entirety or with respect to the Terminated Territory, as applicable) as and to the extent set forth in this Article 12. For purposes of clarity, AbbVie shall not be required to Manufacture or have Manufactured the Licensed Products by or on behalf of Ablynx as part of the Transition Agreement. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3 or by Ablynx in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie and in its name applicable to the Licensed Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) unless expressly prohibited by any Regulatory Authority, transfer control to Ablynx of all Clinical Studies being Conducted by AbbVie as of the effective date of termination and continue to Conduct such Clinical Studies, […***…], for up to […***…] to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Ablynx shall not have any obligation to continue any Clinical Study unless required by Applicable Law, in which case Ablynx, if it wishes to terminate such Clinical Study, shall continue such Clinical Study […***…] until such time that Applicable Law allows such trial to be terminated (with Ablynx taking all reasonable steps to promptly terminate such Clinical Study and minimize all costs and expenses), and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, […***…]; (iv) assign (or cause its Affiliates to assign) to Ablynx all agreements with any Third Party with respect to the conduct of pre-clinical Development activities, Manufacturing or Clinical Studies for the Licensed Products, including agreements with contract research organizations, contract manufacturing organizations, clinical sites, and investigators, unless, with respect to any such agreement, such agreement (a) expressly prohibits such assignment, in which case AbbVie shall cooperate with Ablynx in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (b) covers Clinical Studies for Combination Products in which any active ingredient that is not a Licensed Compound is covered by Patents Controlled by AbbVie or any of its Affiliates or covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Licensed Products, in which case AbbVie shall, […***…], cooperate with Ablynx in all reasonable respects to facilitate the execution of a new agreement between Ablynx and the applicable Third Party; and (v) transfer to Ablynx all existing clinical supplies of the Licensed Compound or Licensed Product in the possession of AbbVie at the time of termination, which shall be […***…]. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. In the event this Agreement is partially terminated or terminated in its entirety by Ablynx pursuant Section 12.2.1, then any actions or activities set forth in the Transition Agreement shall be […***…]. 12.8.3 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3.2 or with respect to a Terminated Territory by Ablynx pursuant to Section 12.2.2 (but not in the case of any termination of this Agreement in its entirety), AbbVie shall in a reasonable amount of time following Ablynx’s request: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Approvals owned by AbbVie and then in its name that is solely applicable to the Terminated Territory and to the Licensed Products that are the subject of an exclusive license grant in Section 12.7.2, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Licensed Products in the Territory, Develop Licensed Products in support of such Commercialization, or Manufacture Licensed Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Ablynx a right of reference to all Regulatory Documentation then owned by AbbVie and in AbbVie’s name that are not transferred to Ablynx pursuant to clause (i) above that are necessary or reasonably useful for Ablynx, any of its Affiliates or sublicensees to Develop or Commercialize any Licensed Products that are the subject of the license grant in Section 12.7.2, as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory.

  • Cooperation Agreement If a Cooperating Institution is appointed, the Fund shall enter into a Cooperation Agreement with the Cooperating Institution setting forth the terms and conditions of its appointment.

  • Arbitration Agreement ANY AND ALL CONTROVERSIES, DISPUTES OR CLAIMS BETWEEN SPARTAN AND YOU OR YOUR AGENTS, REPRESENTATIVES, EMPLOYEES, DIRECTORS, OFFICERS OR CONTROL PERSONS, ARISING OUT OF, IN CONNECTION WITH, OR WITH RESPECT TO (i) ANY PROVISIONS OF OR THE VALIDITY OF THIS AGREEMENT OR ANY RELATED AGREEMENTS, (ii) THE RELATIONSHIP OF THE PARTIES HERETO, OR (iii) ANY CONTROVERSY ARISING OUT OF YOUR BUSINESS SHALL BE CONDUCTED BY THE AMERICAN ARBITRATION ASSOCIATION UNDER ITS COMMERCIAL ARBITRATION RULES OR FINRA ARBITRATION RULES. ARBITRATION MUST BE COMMENCED BY SERVICE OF A WRITTEN DEMAND FOR ARBITRATION OR A WRITTEN NOTICE OF INTENTION TO ARBITRATE. IF YOU ARE A PARTY TO SUCH ARBITRATION, TO THE EXTENT PERMITTED BY THE RULES OF THE APPLICABLE ARBITRATION TRIBUNAL, THE ARBITRATION SHALL BE CONDUCTED IN NEW YORK, NEW YORK. THE DECISION AND AWARD OF THE ARBITRATORS(S) SHALL BE CONCLUSIVE AND BINDING UPON ALL PARTIES, AND ANY JUDGMENT UPON ANY AWARD RENDERED MAY BE ENTERED IN THE STATE OR FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK, OR ANY OTHER COURT HAVING JURISDICTION THEREOF, AND NEITHER PARTY SHALL OPPOSE SUCH ENTRY.